PET scan for tracking immunotherapy in gastrointestinal cancers
Part of Cancer, Digestive system clinical trials.
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a gastrointestinal cancer that your doctor plans to treat with immunotherapy or a combination that includes immunotherapy.
- You are between 18 and 75 years old.
- You are in good overall health and expected to live more than 6 months.
- You do not have serious illnesses like severe heart, lung, liver, or kidney failure, severe bone marrow suppression, or a bowel blockage or perforation.
- You are not pregnant, possibly pregnant, or breastfeeding.
- You are willing and able to follow the study procedures and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working for pancreatic cancer. It may help your doctor understand if your treatment is effective.
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
This trial tests a special PET scan (68Ga-grazytracer) to see if it can predict early whether immunotherapy is working in people with lung cancer that can be surgically removed. If successful, this scan could help doctors tailor treatment sooner.
This trial uses a special PET scan called 68Ga-grazytracer to see how well your soft tissue sarcoma responds to immunotherapy treatment. It may help doctors understand if the treatment is working.
This trial uses a special PET scan (68Ga-grazytracer) to find out whether growth seen on scans after immunotherapy is real cancer growth or a harmless reaction called pseudoprogression. It helps doctors decide if your treatment is working.
This trial uses a special scan (68Ga-grazytracer PET) to see how well immunotherapy works for stage III non-small cell lung cancer before surgery or radiation. It aims to help doctors choose the best treatment for you.
Hear when a new Gastrointestinal Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.